Navigation Links
Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting

asive bladder cancer, that trials evaluating the effects of satraplatin in combination with radiation therapy, in combination with other cancer therapies and in a number of cancer types are underway or planned, that SPI-1620 is expected to enter clinical trials later this year and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates, may not prove safe or effective, the possibility that our existing and new drug candidates may not receive approval from the FDA, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in- license and develop additional drug candidates may fail, our lack of revenues, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.

    COMPANY CONTACTS                    MEDIA CONTACT

    Russell Skibsted                    Susan Neath

    SVP & Chief Business Officer        Porter Novelli Life Sciences

                                        619-849-6007

    Paul Arndt

    Manager, Investor Relations

    949-788-6700

CONTACT: Russell Skibsted, SVP & Chief Business Officer, or Paul ArndtManager, Investor Relations, both of Spectrum Pharmaceuticals, Inc.,+1-949-788-6700; or Media Contact, Susan Neath of Porter Novelli LifeScienc
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
2. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
(Date:7/25/2014)... , July 25, 2014  CVS Caremark Corporation ... conference call on Tuesday, August 5, 2014, at 8:30 ... second quarter 2014 financial results. An audio ... through the Investor Relations portion of the CVS Caremark ... visit http://info.cvscaremark.com/investors . This webcast will be archived ...
(Date:7/25/2014)... 2014  Acsis Inc., the market leader for ... has recently posted an article, "Future of ... future needs for companies, extended supply chain, and ... model no longer work today.  The article explains ... of mobile technology, machine to machine (M2M) connectivity, ...
(Date:7/25/2014)... Research and Markets has announced the addition ... report to their offering. ... An ophthalmic diagnostic device is a ... in the human visual pathway. Ophthalmic devices are used ... glaucoma, retinal disorders, conjunctivitis, and dry eyes. ...
Breaking Medicine Technology:Acsis Addresses Questions on the Modern Supply Chain 2Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2
... on Mayo Clinic Discoveries is Developing Therapies for Wounds, ... Angiogenic Properties , , ... company,s novel technology platform which employs nano-materials made of ... wound healing, diabetic foot ulcers and hair growth are ...
... Dec. 14 Eisai Corporation of North,America today ... (FDA) has,approved LUSEDRA(TM) (fospropofol disodium) Injection, an intravenous,sedative-hypnotic ... adult,patients undergoing diagnostic or therapeutic procedures. , ... the FDA required that LUSEDRA be used only ...
Cached Medicine Technology:OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications 2OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications 3FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation 2FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation 3FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation 4
(Date:7/27/2014)... 2014 Bags underneath the eyes is one ... and there are a range of new products now available ... a baggy eyes serum review that is now posted for ... explores the issues with baggy eyes and how the natural ... users. The guide also provides a detailed overview of the ...
(Date:7/27/2014)... hepatitis E virus (HEV) transmission by blood components indicates ... HEV in their plasma. The findings, published in ... components (eg, red cells, platelets, and fresh frozen plasma) ... , The study retrospectively screened 225 000 individual ... 2012 and Sept, 2013 for HEV RNA. 79 donors ...
(Date:7/27/2014)... Ticket Down is a reputable source for ... California on November 15th. This Australian boy band has recently ... songs from this amazing album at the concert. , Tickets ... The Forum will be released for sale to the general public ... TicketDown.com. This popular secondary ticket exchange can also be reached ...
(Date:7/27/2014)... According to a new market report ... Endoscopic Operative Devices, and Visualization Systems) - Global Industry ... global endoscopy devices market was valued at USD 24.9 ... a CAGR of 6.8% from 2013 to 2019, to ... 2019. , Endoscopy procedures are performed by inserting rod ...
(Date:7/27/2014)... Scientists from The University of Manchester have discovered why medication ... findings, published in Nature Medicine , show that drugs ... clock. , In the UK pneumonia, which is ... each year and is more serious for babies, young children, ... , More than 5 million people in the UK ...
Breaking Medicine News(10 mins):Health News:Baggy Eyes Serum Review Posted for Men and Women at Cherry News Website 2Health News:The Lancet: 1 in 3000 blood donors in England infected with hepatitis E 2Health News:5 Seconds of Summer Tickets at The Forum in Inglewood (Los Angeles), CA Now Available For Sale at Ticket Down 2Health News:Global Endoscopy Devices Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Global Endoscopy Devices Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Global Endoscopy Devices Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:Drugs used to treat lung disease work with the body clock 2
... Directors and Commits all ... Work to Benefit FASTeam, CHICAGO, July 7 Fetal ... Bifida, Down Syndrome and Muscular,Dystrophy combined, yet it is a ... prevention of prenatal alcohol exposure and,research examining the effects of ...
... play a major role in,keeping the bone marrow environment ... Tenn., July 7 The lack of a single,protein ... to,recycle molecules in cells causes an incurable and often ... Hospital investigators., Children with this disease, called sialidosis, ...
... chances of miscarriage for couple, study finds , , MONDAY, ... those in which the man is over age 35 have ... study shows. , To come to this conclusion, French researchers ... fertility clinic in France. , In most of the cases, ...
... San Francisco,s Largest AIDS Fundraising Event Goes GREEN with Online ... Communications, Recycling and Awareness, ... AIDS Walk San Francisco announced today key initiatives to ,Green, ... The,initiatives include the introduction of Green Walkers, composting, and,enhanced recycling., ...
... Athens Regional Medical Center and,Blue Cross and Blue ... multi-year contract, enabling Athens Regional to join the BCBSGa,HMO/POS ... PPO contract with,Athens Regional for many years., The ... throughout,Georgia will be able to gain complete access to ...
... Physicians Practice, America,s,Leading Practice Management Journal today ... to editorial director, Steven Gottshall to associate,publisher, ... promotions,are reflective of the company,s overall strategy ... into new physician focused markets and,circulation growth., ...
Cached Medicine News:Health News:K Squared Sponsors F.A.S.T. Ride 150-mile Motorcycle Tour August 17 2Health News:St. Jude Study Reveals a New Function for an Old Enzyme in Fatal Childhood Disease 2Health News:St. Jude Study Reveals a New Function for an Old Enzyme in Fatal Childhood Disease 3Health News:St. Jude Study Reveals a New Function for an Old Enzyme in Fatal Childhood Disease 4Health News:Father's Age a Factor in Infertility 2Health News:AIDS Walk San Francisco Takes Big Green Step Forward 2Health News:AIDS Walk San Francisco Takes Big Green Step Forward 3Health News:Blue Cross and Blue Shield of Georgia and Athens Regional Medical Center Announce New HMO/POS Contract 2Health News:Physicians Practice Promotes Key Executives 2
... Pupillometry in Critical Care & Emergency ... a hand-held, cordless, and simple to use ... the measurement of the pupillary light reflex ... pupillary function which are not discernable to ...
...
Inquire...
Using proven 1064 nm technology for the treatment of deeper lesions, the Lumenis One Multi-Spot Nd:YAG module provides versatility allowing targeted treatment of leg veins, vascular lesions, facial w...
Medicine Products: